Literature DB >> 31289360

MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.

Nathanael H Green1,2, Daniel L Galvan2, Shawn S Badal2, Benny H Chang3, Valerie S LeBleu4, Jianyin Long2, Eric Jonasch5, Farhad R Danesh6,7.   

Abstract

One-carbon metabolism plays a central role in a broad array of metabolic processes required for the survival and growth of tumor cells. However, the molecular basis of how one-carbon metabolism may influence RNA methylation and tumorigenesis remains largely unknown. Here we show MTHFD2, a mitochondrial enzyme involved in one-carbon metabolism, contributes to the progression of renal cell carcinoma (RCC) via a novel epitranscriptomic mechanism that involves HIF-2α. We found that expression of MTHFD2 was significantly elevated in human RCC tissues, and MTHFD2 knockdown strongly reduced xenograft tumor growth. Mechanistically, using an unbiased methylated RNA immunoprecipitation sequencing (meRIP-Seq) approach, we found that MTHFD2 plays a critical role in controlling global N6-methyladenosine (m6A) methylation levels, including the m6A methylation of HIF-2α mRNA, which results in enhanced translation of HIF-2α. Enhanced HIF-2α translation, in turn, promotes the aerobic glycolysis, linking one-carbon metabolism to HIF-2α-dependent metabolic reprogramming through RNA methylation. Our findings also suggest that MTHFD2 and HIF-2α form a positive feedforward loop in RCC, promoting metabolic reprograming and tumor growth. Taken together, our results suggest that MTHFD2 links RNA methylation status to the metabolic state of tumor cells in RCC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31289360      PMCID: PMC8040069          DOI: 10.1038/s41388-019-0869-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Abnormal cholesterol metabolism in renal clear cell carcinoma.

Authors:  R L Gebhard; R V Clayman; W F Prigge; R Figenshau; N A Staley; C Reesey; A Bear
Journal:  J Lipid Res       Date:  1987-10       Impact factor: 5.922

2.  NCBI GEO: archive for functional genomics data sets--update.

Authors:  Tanya Barrett; Stephen E Wilhite; Pierre Ledoux; Carlos Evangelista; Irene F Kim; Maxim Tomashevsky; Kimberly A Marshall; Katherine H Phillippy; Patti M Sherman; Michelle Holko; Andrey Yefanov; Hyeseung Lee; Naigong Zhang; Cynthia L Robertson; Nadezhda Serova; Sean Davis; Alexandra Soboleva
Journal:  Nucleic Acids Res       Date:  2012-11-27       Impact factor: 16.971

  2 in total
  41 in total

1.  Detection and characterisation of novel alternative splicing variants of the mitochondrial folate enzyme MTHFD2.

Authors:  Vicky Nicolaidou; Christos Papaneophytou; Costas Koufaris
Journal:  Mol Biol Rep       Date:  2020-09-03       Impact factor: 2.316

Review 2.  The evolving metabolic landscape of chromatin biology and epigenetics.

Authors:  Ziwei Dai; Vijyendra Ramesh; Jason W Locasale
Journal:  Nat Rev Genet       Date:  2020-09-09       Impact factor: 53.242

Review 3.  Reprogramming of serine, glycine and one-carbon metabolism in cancer.

Authors:  Albert M Li; Jiangbin Ye
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-05-19       Impact factor: 5.187

4.  MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

Authors:  Ayaka Sugiura; Gabriela Andrejeva; Kelsey Voss; Darren R Heintzman; Xincheng Xu; Matthew Z Madden; Xiang Ye; Katherine L Beier; Nowrin U Chowdhury; Melissa M Wolf; Arissa C Young; Dalton L Greenwood; Allison E Sewell; Shailesh K Shahi; Samantha N Freedman; Alanna M Cameron; Patrik Foerch; Tim Bourne; Juan C Garcia-Canaveras; John Karijolich; Dawn C Newcomb; Ashutosh K Mangalam; Joshua D Rabinowitz; Jeffrey C Rathmell
Journal:  Immunity       Date:  2021-11-11       Impact factor: 31.745

Review 5.  A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight.

Authors:  Christine R Cuthbertson; Zahra Arabzada; Armand Bankhead; Armita Kyani; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-01

6.  MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway.

Authors:  Jun Huang; Yinyin Qin; Canfeng Lin; Xiaoguang Huang; Feiran Zhang
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

7.  Alteration of N6-methyladenosine epitranscriptome profile in lipopolysaccharide-induced mouse mesangial cells.

Authors:  Tao Liu; Xing Xing Zhuang; Xiu Juan Qin; Liang Bing Wei; Jia Rong Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-04       Impact factor: 3.000

Review 8.  Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer.

Authors:  Aamod S Dekhne; Zhanjun Hou; Aleem Gangjee; Larry H Matherly
Journal:  Mol Cancer Ther       Date:  2020-09-02       Impact factor: 6.261

Review 9.  Folate pathways mediating the effects of ethanol in tumorigenesis.

Authors:  Jaspreet Sharma; Sergey A Krupenko
Journal:  Chem Biol Interact       Date:  2020-04-10       Impact factor: 5.192

10.  Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma.

Authors:  Yuanyuan Guo; Beibei Liu; Yihan Liu; Wei Sun; Wuyue Gao; Shilong Mao; Li Chen
Journal:  Front Cell Dev Biol       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.